Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Ocugen, Inc. filings on SEC EDGAR ↗
Ocugen granted Celairis Therapeutics an exclusive license to commercialize its OCU400 gene therapy for retinitis pigmentosa in Australia, New Zealand, and ASEAN markets. Ocugen will receive up to $7.1 million in upfront and milestone payments, plus high single-digit royalties and 50% of gross profits from net sales. Ocugen retains sole manufacturing rights and expects to enter a formal supply agreement within 90 days.
Ocugen is transitioning to a late-stage clinical company with three Phase 3 programs, targeting BLA filings by 2028 and leveraging international licensing for non-dilutive capital.
Ocugen, Inc. reported total assets of $108.1 million as of September 30, 2026, a significant increase from $43.5 million at the end of 2025, primarily driven by $59.6 million in new short-term investments. The company is currently advancing its Phase 3 trial for OCU400 and Phase 2/3 trial for OCU410ST while maintaining its status as a non-accelerated filer and smaller reporting company.
Ocugen reported Q3 2026 financial results, highlighting a cash position of $84.6 million with an expected runway into 2028. The company advanced its gene therapy pipeline, including the initiation of the Phase 3 ArMaDa3 trial for OCU410 and receiving provisional approval for OCU400 in The Bahamas.
Term
Q3 2026
“With three Phase 3 modifier gene therapy programs underway, Ocugen is executing against a clear strategy of advancing our pipeline and leveraging strategic partnerships to expand global reach and potentially bring our therapies to patients worldwide.”
Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen
“As we demonstrated in the third quarter, we remain focused on executing key clinical and regulatory milestones, expanding our commercial opportunities, and maintaining a disciplined approach as we advance toward the anticipated OCU400 Phase 3 topline data early next year.”
Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen
Ocugen, Inc. filed a formal investor presentation deck for October 2026 detailing its strategic pipeline and clinical milestones. The company is targeting three Biologics License Applications (BLAs) by 2028 for its gene therapy candidates OCU400, OCU410, and OCU410ST, which address major blindness diseases.
Ocugen Licensing Deal with Roots Pharmaceutical Company WLL Worth $259M
Ocugen granted Roots Pharmaceutical an exclusive license to commercialize OCU400, a modifier gene therapy for retinitis pigmentosa, in the Middle East and North Africa. Ocugen will receive up to $4 million in upfront and development milestones, up to $255 million in sales milestones, and a 22% royalty on net sales. Ocugen also entered into a commercial supply agreement to manufacture the product for Roots.
Shankar Musunuri, CEO, sold 525,991 shares of Ocugen, Inc. at $0.95 a share, worth $500K in total on Oct 9, 2026. Shares held after the trade: 1,030,771 (-5.3%).
Ocugen, Inc. reconvened its Special Meeting of Stockholders on October 5, 2026, but adjourned it again until October 26, 2026. The adjournment is intended to provide additional time for stockholders to vote on a proposal to increase the number of authorized shares of common stock by 250,000,000.
Ocugen, Inc. held a Special Meeting of Stockholders on September 21, 2026, where shareholders approved a proposal to adjourn the meeting to solicit additional proxies. The meeting was adjourned to October 5, 2026, specifically to allow more time for stockholders to vote on a proposal to increase the number of authorized shares of common stock by 250,000,000.
Shankar Musunuri, CEO, sold 525,991 shares of Ocugen, Inc. at $1.12 a share, worth $589K in total on Sep 9, 2026. Shares held after the trade: 1,088,035 (-5.0%).